DrugPatentWatch Database Preview
Apgdi Company Profile
What is the competitive landscape for APGDI, and what generic alternatives to APGDI drugs are available?
APGDI has one approved drug.
There are seven US patents protecting APGDI drugs.
There are one hundred and eight patent family members on APGDI drugs in twenty-nine countries and sixteen supplementary protection certificates in eleven countries.
Summary for Apgdi
| International Patents: | 108 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Apgdi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | RX | Yes | Yes | 6,346,532 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | RX | Yes | Yes | 7,982,049 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | RX | Yes | Yes | 7,342,117 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Apgdi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | 6,699,503 | ➤ Try a Free Trial |
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | 6,699,503 | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for APGDI drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 25 mg and 50 mg | ➤ Subscribe | 2016-06-28 |
Non-Orange Book US Patents for Apgdi
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,750,029 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Apgdi Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Norway | 20020516 | ➤ Try a Free Trial |
| New Zealand | 539577 | ➤ Try a Free Trial |
| Germany | 69823858 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Apgdi Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 1559427/01 | Switzerland | ➤ Try a Free Trial | PRODUCT NAME: MIRABEGRON; REGISTRATION NO/DATE: SWISSMEDIC 62755 19.05.2014 |
| 90028-7 | Sweden | ➤ Try a Free Trial | PRODUCT NAME: MIRABEGRON ELLER ETT SALT DAERAV; REG. NO/DATE: EU/1/12/809/001 20121220 |
| 0130015 00094 | Estonia | ➤ Try a Free Trial | PRODUCT NAME: MIRABEGROON;REG NO/DATE: K(2012)9945 (LOPLIK) 20.12.2012 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
